Immunology & Autoimmune
Part of Biotech - Drug Development
 JNJ | Johnson & Johnson | $0.6t | $266.27 | -1.3% | 4.2M |
 ABBV | ABBVIE INC. | $443.4b | $258.16 | -1.7% | 1.6M |
 AMGN | Amgen Inc | $207.9b | $438.21 | -0.4% | 888.0K |
 BMY | Bristol-Myers Squibb Co. | $133.4b | $67.17 | -0.5% | 2.2M |
 REGN | Regeneron Pharmaceuticals Inc | $78.2b | $810.97 | -0.2% | 330.5K |
 ROIV | Roivant Sciences Ltd. Common Shares | $24.1b | $37.14 | +0.9% | 2.0M |
 APGE | Apogee Therapeutics, Inc. Common Stock | $10.1b | $134.97 | +0.0% | 470.1K |
 PTGX | Protagonist Therapeutics, Inc | $8.5b | $150.52 | -0.7% | 203.3K |
 SYRE | Spyre Therapeutics, Inc. Common Stock | $8.2b | $93.57 | +0.2% | 705.8K |
 IMVT | Immunovant, Inc. Common Stock | $7.9b | $43.56 | -0.6% | 262.0K |
 IBRX | ImmunityBio, Inc. Common Stock | $7.5b | $8.51 | +3.7% | 8.6M |
 TGTX | TG Therapeutics, Inc. | $7.1b | $55.09 | -0.1% | 531.1K |
 DNTH | Dianthus Therapeutics, Inc. Common Stock | $5.8b | $111.20 | +0.4% | 152.1K |
 ORKA | Oruka Therapeutics, Inc. Common Stock | $5.7b | $97.21 | -2.0% | 215.7K |
 APLS | Apellis Pharmaceuticals, Inc. Common Stock | $5.2b | $41.04 | +0.0% | 68.6M |
 ALMS | Alumis Inc. Common Stock | $3.6b | $23.52 | +0.2% | 251.3K |
 RCUS | Arcus Biosciences, Inc. | $3.5b | $30.61 | -0.6% | 345.4K |
 ARQT | Arcutis Biotherapeutics, Inc. Common Stock | $3.4b | $25.00 | -1.0% | 729.2K |
 CLDX | Celldex Therapeutics, Inc | $3.0b | $40.87 | +0.7% | 163.2K |
 NKTR | Nektar Therapeutics | $2.4b | $74.47 | +1.4% | 189.3K |
 VERA | Vera Therapeutics, Inc. Class A Common Stock | $2.3b | $34.42 | -6.4% | 1.8M |
 BHVN | Biohaven Ltd. | $2.0b | $15.79 | -6.8% | 3.5M |
 ZBIO | Zenas BioPharma, Inc. Common Stock | $2.0b | $32.65 | -1.8% | 344.0K |
 ADMA | ADMA Biologics, Inc. | $2.0b | $9.41 | -2.0% | 654.7K |
 AUPH | Aurinia Pharmaceuticals Inc | $1.9b | $16.55 | 0.0% | 447.4K |
 ANAB | AnaptysBio, Inc. Common Stock | $1.7b | $57.50 | -0.9% | 397.4K |
 SEPN | Septerna, Inc. Common Stock | $1.6b | $40.44 | +0.6% | 75.0K |
 FBRX | Forte Biosciences, Inc. Common Stock | $1.6b | $76.98 | 0.0% | N/A |
 MLTX | MoonLake Immunotherapeutics Class A Ordinary Shares | $1.5b | $15.62 | -0.0% | 613.2K |
 XNCR | Xencor, Inc. | $1.4b | $28.52 | -0.2% | 559.9K |
 JBIO | Jade Biosciences, Inc. Common Stock | $1.2b | $21.60 | +0.8% | 141.2K |
 CRVS | Corvus Pharmaceuticals, Inc. | $1.1b | $14.89 | +1.4% | 216.8K |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.0b | $22.59 | -0.2% | 257.6K |
 AVTX | Avalo Therapeutics, Inc. Common Stock | $1.0b | $20.20 | -1.6% | 142.5K |
 ANNX | Annexon, Inc. Common Stock | $0.8b | $5.29 | +6.3% | 1.9M |
 DBVT | DBV Technologies S.A. | $0.8b | $14.42 | -0.3% | 108.6K |
 ACRS | Aclaris Therapeutics, Inc. | $0.7b | $6.19 | -0.1% | 583.6K |
 STTK | Shattuck Labs, Inc. Common Stock | $0.7b | $7.73 | -2.4% | 318.4K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.7b | $46.73 | +0.8% | 73.8K |
 CLYM | Climb Bio, Inc. Common Stock | $0.7b | $15.18 | -4.3% | 687.1K |
 IMMX | Immix Biopharma, Inc. Common Stock | $0.6b | $14.43 | +2.2% | 801.8K |
 ZURA | Zura Bio Limited Class A Ordinary Shares | $0.6b | $5.89 | -1.7% | 648.5K |
 QTTB | Q32 Bio Inc. Common Stock | $450.5m | $16.02 | -0.4% | 86.1K |
 KYTX | Kyverna Therapeutics, Inc. Common Stock | $443.8m | $8.71 | +1.0% | 246.6K |
 CABA | Cabaletta Bio, Inc. Common Stock | $437.0m | $3.37 | +3.2% | 2.5M |
 EVMN | Evommune, Inc. | $405.2m | $13.70 | -3.2% | 144.1K |
 ENTA | Enanta Pharmaceuticals, Inc | $366.4m | $13.95 | -1.7% | 111.7K |
 IPSC | Century Therapeutics, Inc. Common Stock | $364.3m | $2.21 | +3.3% | 345.4K |
 UPB | Upstream Bio, Inc. Common Stock | $349.4m | $6.83 | -2.9% | 134.5K |
 PALI | Palisade Bio, Inc. Common Stock | $337.1m | $2.10 | -1.2% | 548.3K |